A r t i c l e s CD8 + T cells (cytotoxic T lymphocytes (CTLs)) form a critical arm of the adaptive immune system by providing immunity to various intracellular pathogens and malignant cells. MicroRNAs are small noncoding RNAs approximately 22 nucleotides in length that have been identified as key modulators of post-transcriptional gene modulation in mammals [1] [2] [3] [4] . The importance of microRNAs in T cell immunity is emphasized by the finding that CD4 + T cells lacking Dicer, an enzyme critical for the maturation of microRNA 1, [5] [6] [7] , have impaired responses 8 . Deletion of Dicer in CD8 + T cells results in a smaller effector CD8 + T cell population as a consequence of impaired migration and survival 9 . However, the role of individual microRNAs in the CD8 + T cell response is largely unexplored.
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One microRNA with an emerging role in regulating immune responses is miR-155 (ref. 10 ). This microRNA is essential for normal B cell differentiation and antibody production [11] [12] [13] and is involved in inflammation by regulating members of the superfamilies of tumornecrosis factor (TNF) receptors and their ligands, such as TNF and TRAMP (TNFRSF25) 14, 15 . Dendritic cells deficient in miR-155 fail to efficiently present antigens 11 , whereas miR-155 in CD4 + T cells controls differentiation into the T H 1, T H 2 and T H 17 subsets of helper T cells 11, 12, 16 and affects the development of regulatory T cells 17, 18 . It is also reported to regulate CD8 + T cells 19, 20 . Thus, miR-155 may control protective immune responses and inflammation in many ways.
Here we found much higher miR-155 expression in CD8 + T cells after activation in vitro, as well as in antigen-specific effector CD8 + T cells in vivo. Naive and central memory cells had low miR-155 expression, whereas effector memory cells had intermediate miR-155 expression.
We found miR-155 was intrinsically required for optimal primary CD8 + T cell responses mounted against infection with influenza virus or Listeria monocytogenes and was crucial for the generation of CD8 + T cell memory against these pathogens. We determined that miR-155 was important for the proliferation of CD8 + T cells and affected many of its own predicted targets and other genes associated with type I interferon signaling. Moreover, miR-155 regulated the antiproliferative effect of type I interferon, which may explain the paradox that interferon both serves as a positive signal 21, 22 and has a negative antiproliferative effect [23] [24] [25] .
RESULTS

Expression of miR-155 by CD8 + T cells
We first investigated whether the activation and differentiation status of CD8 + T cells affected miR-155 expression. After in vitro stimulation, naive CD8 + T cells rapidly increased their expression of miR-155. Activation of purified CD8 + T cells for 24 h with solid-phase antibody to CD3 (anti-CD3) and anti-CD28 resulted in a 42-fold higher miR-155 expression than that in unstimulated naive CD8 + T cells. On days 3 and 5 of activation, expression of miR-155 further increased to 83-and 104-fold, respectively, that of naive unstimulated control cells (Fig. 1a) . Treatment of unstimulated naive CD8 + T cells for 24 h with 10 ng/ml of TNF, interferon-γ (IFN-γ) or interleukin 1β (IL-1β) or 1,000 U/ml of IFN-β did not affect miR-155 expression, whereas in activated cells it resulted in twofold higher miR-155 expression (Supplementary Fig. 1a) .
To determine if miR-155 was also expressed in vivo during CD8 + T cell responses, we adoptively transferred Thy-1.1 + OT-I cells (which VOLUME 14 NUMBER 6 JUNE 2013 nature immunology A r t i c l e s have transgenic expression of a T cell antigen receptor (TCR) specific for the immunodominant epitope of ovalbumin (OVA) amino acids 257-264 (OVA(257-264)) into congenic Thy-1.2 + mice, then infected the recipient mice with recombinant influenza virus strain A/WSN/33 expressing OVA(257-264) (WSN-OVA). We then isolated donor OT-I CD8 + T cells from the recipient mice and measured miR-155 in the cells. At day 10, effector CD44 + CD62L − donor OT-I cells from the lungs of recipient mice had 11-fold higher miR-155 expression than that of naive CD44 − CD62L + OT-I cells (Fig. 1b) . In contrast, by day 60, central memory CD44 + CD62L + donor OT-I cells from the spleens of recipient mice had downregulated miR-155 expression to the amount in naive cells (1.2-fold that of naive CD8 + T cells; Fig. 1b) . The effector memory CD44 + CD62L − donor OT-I cell subset from the spleens of recipient mice at day 60 had 4.4-fold higher miR-155 expression than that of naive cells (Fig. 1b) 
CD8 + T cell responses require miR-155
To determine whether miR-155 has a role in CD8 + T cell responses in vivo, we infected miR-155-deficient and wild-type C57BL/6 mice with a sublethal dose of influenza virus, strain A/PR/8/34. We identified antigen-specific CD8 + T cells by surface staining with tetramers of major histocompatibility complex class I loaded with the influenza virus nucleoprotein immunodominant epitope of amino acids 366-374 (NP(366-374)). We found a much lower frequency and number of lung NP(366-374)-specific CD8 + T cells in miR-155-deficient mice than in wild-type mice at the peak of the CD8 + T cell response (day 10); wild-type mice had sixfold more NP(366-374)-specific pulmonary CD8 + T cells than did their miR-155-deficient counterparts (Fig. 2a,b) . We also observed a lower abundance of NP(366-374)-specific CD8 + T cells in mediastinal lymph nodes and spleens of miR-155-deficient mice (data not shown). The diminished CD8 + T cell response in miR-155-deficient mice was accompanied by impaired viral clearance (Fig. 2c) . The diminished CD8 + T cell response was not due to defects in the generation and differentiation of these cells in miR-155-deficient mice, as the number, naivememory phenotype (as defined by expression of CD62L, CD44, KLRG1, CD127, CD27 and CD28) and activation status (as defined by expression of CD69 and CD25) of splenic CD8 + T cells in uninfected miR-155-deficient mice did not differ from that in their wild-type counterparts (data not shown and Supplementary Fig. 1b) .
As miR-155 is known to affect many types of cells of the immune response [11] [12] [13] 17, 18 , we sought to determine whether miR-155 deficiency conferred an intrinsic defect in the ability of CD8 + T cells to respond to pathogens. We generated CD45.2 + miR-155-deficient OT-I mice (on a C57BL/6 background) and adoptively transferred 1 × 10 4 CD45.2 + OT-I or miR-155-deficient OT-I cells into congenic CD45.1 + wild-type mice and infected the recipient mice with influenza virus WSN-OVA. At day 10 after infection, hosts given miR-155-deficient OT-I cells had 98% fewer OVA(257-264)-specific donor CD8 + T cells in their lungs than did recipients of OT-I cells (Fig. 2d,e) . We also found a lower abundance of miR-155-deficient OT-I cells in mediastinal lymph nodes and spleens ( Fig. 2e) , which indicated that the survival and/or proliferation, but not the trafficking, of CD8 + T cells was affected by miR-155 deficiency. The diminished peak response of miR-155-deficient OT-I cells was not due to a shift in the kinetics (Fig. 2f) . Deficiency in miR-155 was affecting later stages of the primary CD8 + T cell response to influenza virus, because early time points (such as day 4) were not affected (Supplementary Fig. 1c) . The naive-memory phenotype (as defined by expression of CD62L, CD44, KLRG1, CD127, CD27 and CD28) and activation status (as defined by expression of CD69 and CD25) of miR-155-deficient OT-I cells was not different from that of OT-I cells on days 4 and 10 after infection (data not shown).
To determine whether miR-155 deficiency affected CD8 + T cell responses to bacterial infection, we adoptively transferred Thy-1.1 + OT-I or miR-155-deficient OT-I cells into Thy-1.2 + congenic mice and infected the recipient mice with OVA-expressing L. monocytogenes. Recipients of OT-I CD8 + T cells had 15-fold more OVA(257-264)-specific donor CD8 + T cells on day 7 after infection in spleens than did recipients of miR-155-deficient OT-I cells (Fig. 2g,h) . We also found a lower abundance of miR-155-deficient OT-I cells in the mesenteric lymph nodes (Fig. 2h) . Similar to the response to influenza virus, during infection with OVA-expressing L. monocytogenes, the responses of miR-155-deficient OT-I cells were not diminished early in the response (Supplementary Fig. 1d) .
Finally, to evaluate the role of miR-155 in the establishment of CD8 + T cell memory, we adoptively transferred 1 × 10 4 CD45.2 + OT-I or miR-155-deficient OT-I cells into CD45.1 + mice and then infected the recipient mice with influenza virus WSN-OVA. At day 60 after infection, there were 37-fold more OT-I donor memory cells than miR-155-deficient OT-I donor memory cells in the spleen (Fig. 2i,j) . We also found a lower abundance of miR-155-deficient OT-I memory cells in the mediastinal lymph nodes and the lungs ( Supplementary  Fig. 1e ). When we analyzed short-lived effector cells and memory precursor effector cells during the primary response, we found that miR-155 deficiency impaired the abundance of each population (Supplementary Fig. 1f ). These findings indicated that miR-155 was required for the establishment of a CD8 + T cell memory pool during pathogenic infection. This was most probably due to the requirement for miR-155 for the generation of memory precursor cells during the primary response, although we cannot exclude the possibility of effects on the differentiation or maintenance of memory cells. However, there were fewer short-lived and memory precursor npg effector cell during the primary response; thus, miR-155 had a global effect on the population expansion of CD8 + T cells and did not selectively affect memory precursor cells. These data collectively demonstrated that miR-155 had an intrinsic role in regulating primary CD8 + T cell responses to viral and bacterial pathogens and affected the establishment of memory CD8 + T cells.
Overexpression of miR-155 augments CD8 + T cell responses
As miR-155 deficiency inhibited CD8 + T cell responses, we investigated whether miR-155 overexpression would enhance CD8 + T cell immunity. To address this, we transduced Thy-1.1 + OT-I CD8 + T cells with control retroviral MigR1 vector expressing green fluorescent protein (GFP) alone or MigR1 vector expressing miR-155 plus GFP. After 48 h, we transferred 1 × 10 2 donor GFP + OT-I CD8 + T cells intravenously into Thy-1.2 + C57BL/6 mice, then infected the recipients with influenza virus WSN-OVA. At 10 d after infection, the pulmonary OT-I cell population transduced with miR-155-expressing MigR1 had expanded five times more (3,845-fold ± 1,702-fold more than the number of transferred cells) than had the OT-I cells transduced with control vector (766-fold ± 164-fold expansion; 
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and produced more IFN-γ but not more TNF (Fig. 3b) . We obtained similar results for the mediastinal lymph nodes and spleen (data not shown). Mice given OT-I cells transduced with miR-155-expressing MigR1 also had lower viral loads (Fig. 3c) . Thus, overexpression of miR-155 augmented CD8 + T cell responses.
Regulation of proliferation and type I interferon sensitivity
To investigate whether miR-155 could affect early TCR signaling, as does miR-181a 26,27 , we analyzed calcium (Ca 2+ ) flux. We loaded purified CD8 + T cells with the fluorescent Ca 2+ indicator Fluo-4, stimulated the cells with anti-CD3 and measured Ca 2+ flux by flow cytometry. We found that after stimulation with anti-CD3, miR-155-deficient CD8 + T cells fluxed Ca 2+ to an extent similar to that of wild-type CD8 + T cells (Fig. 4a) . In addition, miR-155-deficient CD8 + T cells had normal expression of the activation markers CD25 and CD69 at 24 h after activation (data not shown). These data showed that early TCR signaling was unaffected in miR-155-deficient CD8 + T cells.
To determine whether the diminished in vivo responses of miR-155-deficient CD8 + T cells were due to impaired proliferation, we purified splenic OT-I or miR-155-deficient OT-I cells, labeled them with the cytosolic dye CFSE and stimulated them with OVA(257-264)-pulsed irradiated splenocytes and IL-2 (10 U/ml). After 4 d, miR-155-deficient OT-I populations had 54% fewer cells in division 5, 87% fewer cells in division 6 and 90% fewer cells in division 7 than did OT-I populations (Fig. 4b) , accompanied by significantly fewer miR-155-deficient OT-I CD8 + T cells than OT-I CD8 + T cells in divisions 5-7 (Fig. 4c) . We also found a proliferative defect in miR-155-deficient CD8 + T cells after stimulation with solid-phase anti-CD3 plus IL-2, as miR-155-deficient CD8 + T cells had less incorporation of [ 3 H]thymidine than did wild-type CD8 + T cells (Fig. 4d) . After peptide stimulation, miR-155-deficient OT-I cells did not have significantly more in vitro apoptosis than that of their OT-I counterparts (Supplementary Fig. 2a ). They also did not have more spontaneous, CD95-induced apoptosis or activation-induced cell death after 72 h of culture or more ex vivo apoptosis (determined by annexin V staining) in influenza virus-infected mice (data not shown). As miR-155 can regulate cytokine production 11, 28 , we also assessed the production of IL-2, IFN-γ, TNF, IL-4 and IL-5 in vitro and expression of IFN-γ and TNF in vivo and found no difference between miR-155-deficient and wild-type CD8 + T cells (data not shown and Supplementary Fig. 2b ).
As type I interferon signaling can regulate CD8 + T cell responses 21, 22, 24, 25 and our gene-expression analysis (reported below) indicated that miR-155-deficient CD8 + T cells may have enhanced type I interferon signaling, we assessed the effect of type I interferon on proliferation. For this, we stimulated OT-I and miR-155-deficient OT-I cells with OVA(257-264)-pulsed irradiated splenocytes, treated the cells with IFN-β1 and, 3 and 5 d later, measured incorporation of the thymidine analog BrdU. Treatment with IFN-β1 resulted in less BrdU incorporation in stimulated miR-155-deficient OT-I cells than in their OT-I counterparts at day 5 but not day 3 of culture ( Fig. 4e,f) . In cultures assessed at day 5, IFN-β1 treatment resulted in a 60% lower frequency of BrdU + miR-155-deficient OT-I cells (Fig. 4f) . In contrast, treatment of OT-I CD8 + T cells with IFN-β1 resulted in only slightly fewer BrdU + cells (Fig. 4e,f) . We still observed inhibition of BrdU + miR-155-deficient OT-I cells in cultures at day 6 after we added IFN-β1 after day 3 of culture ( Supplementary Fig. 2c,d) . Adding or blocking IFN-γ had no effect on the proliferation of miR-155-deficient cells (data not shown and Supplementary Fig. 2d ). These results suggested that miR-155 deficiency conferred a proliferative defect on CD8 + T cells and may have enhanced their susceptibility to type I interferon-mediated inhibition.
Enhanced interferon signaling in miR-155-deficient CD8 + T cells To elucidate the molecular mechanisms affected in miR-155-deficient CD8 + T cells, we compared the gene-expression profiles of unstimulated and activated CD8 + T cells from wild-type and miR-155-deficient mice. Significance analysis of microarray did not identify a distinct transcriptional profile for unstimulated miR-155-deficient CD8 + T cells relative to that of wild type cells, with only eight genes being identified as having different expression in unstimulated miR-155-deficient CD8 + T cells (delta value, 1.6; false-discovery rate, 0.066; Fig. 5a ). Activated wild-type and miR-155-deficient CD8 + T cells, however, had 845 genes with different expression (delta value, 1.6; false-discovery rate, 0.082; Fig. 5a ), most of which had a difference in expression of less than twofold (Supplementary that the absence of miR-155 had a moderate effect on large numbers of transcripts rather than having a robust effect on individual targets. We next used the 250 genes with the greatest difference in expression, as identified by significance analysis of microarray, to investigate which molecular pathways were affected by miR-155 deficiency, through the use of Ingenuity pathway analysis (IPA). Those 250 genes in activated miR-155-deficient CD8 + T cells showed enrichment for gene sets of the interferon signaling (P = 0.0002), interferon-regulatory factor (IRF)-regulated (P = 0.006), pyrimidine metabolism (P = 0.001), retinoic acid-mediated apoptosis signaling (P = 0.001) and aryl hydrocarbon receptor signaling (P = 0.003) pathways. Many genes of a molecular network associated with IRF and type I interferon with relevance to cellular responses to infections were upregulated in activated miR-155-deficient CD8 + T cells (Fig. 5b) . Furthermore, by gene-set enrichment analysis, we compared the transcriptome signatures of activated wild-type and miR-155-deficient CD8 + T cells with previously defined transcriptome signatures of interferon-regulated genes. The transcriptome of miR-155-deficient CD8 + T cells showed significant enrichment for the transcriptome signatures of CD8 + T cells stimulated in vitro with IFN-α 29 , and, to a lesser extent, that of IFN-γ-stimulated endothelial cells 30 , relative to that of wild-type CD8 + T cells (Fig. 5c) . In contrast, neither wild-type nor miR-155-deficient CD8 + T cells showed enrichment for an IL-12-dependent molecular signature of in vitro-activated CD8 + T cells 29 (Fig. 5c) . These results demonstrated a role for miR-155 in regulating interferon signaling in CD8 + T cells.
To identify direct targets of miR-155 in CD8 + T cells, we used the TargetScan database (release 6.1, March 2012) and found 299 predicted targets of miR-155, which we then hierarchically clustered. This showed a cluster of 104 miR-155 target genes suppressed (>1.2-fold; q value, <0.05) during activation of wild-type CD8 + T cells (Fig. 6a) . However, 28% of those genes were significantly less downregulated in activated miR-155-deficient CD8 + T cells (>1.2-fold higher expression in activated miR-155-deficient CD8 + T cells than in activated wildtype CD8 + T cells; Fig. 6b and Table 1 ), which suggested that miR-155 may regulate CD8 + T cells by targeting this subset.
To identify miR-155 targets that may mediate the enhanced type I interferon signaling of miR-155-deficient CD8 + T cells, we examined some of the miR-155 targets with the greatest difference in expression in the microarrays that were reported to be involved in interferon signaling. Two such miR-155 targets were Ikbke (which encodes the kinase IKKε) 29, 30 and Bach1 (which encodes the transcriptional repressor Bach1) 31 . We confirmed higher expression of these genes in stimulated miR-155-deficient OT-I by quantitative RT-PCR (Fig. 6c) , as well as higher expression of IKKε protein (Supplementary Fig. 3a) . 
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To directly assess the involvement of IKKε and Bach1 in the phenotype of miR-155-deficient CD8 + T cells, we generated IKKε-deficient miR-155-deficient OT-I mice and transduced miR-155-deficient OT-I cells with a retrovirus expressing Bach1-specific short hairpin RNA (shRNA), then adoptively transferred those cells into wild-type mice that we subsequently infected with influenza virus WSN-OVA. We found that neither IKKε deficiency nor knockdown of Bach1 restored the miR-155-deficient CD8 + T cell response ( Supplementary  Fig. 3b) . We next assessed several miR-155 target genes reported to be affected with miR-155 deficiency. The signaling inhibitor SOCS1 has been linked to the phenotype of miR-155-deficient regulatory T cells 18 . Although the amount of SOCS1 mRNA increased with activation in CD8 + T cells, it was not greater in miR-155-deficient CD8 + T cells (Supplementary Fig. 3c,d) . To further assess the involvement of SOCS1, we treated purified miR-155-deficient OT-I CD8 + T cells with small interfering RNA (siRNA) targeting SOCS1 or transduced them with retrovirus expressing shRNA targeting SOCS1 and then adoptively transferred those cells into wild-type mice, which we then infected with influenza virus WSN-OVA. We found that this did not restore the CD8 + T cell response, despite efficient knockdown of SOCS1 (Supplementary Fig. 3e-g ). Thus, it was unlikely that SOCS1 was the key mediator of the proliferative defect of miR-155-deficient CD8 + T cells. We also assessed other miR-155 targets that may affect T cell activation, such as the phosphatase SHIP-1 (refs. 32,33), or that may affect phosphorylation of the transcription factor STAT5, such as the signal transducer Smad2 (ref. 34 ). We assessed these by immunoblot analysis of unstimulated or activated miR-155 deficient CD8 + T cells and found no effect of miR-155 deficiency on their expression (Supplementary Fig. 3h ). These results collectively raised the possibility that the profound cellular defects of miR-155-deficient CD8 + T cells may have been not due to the dysregulation of a single target gene but resulted from the synergistic effects of many groups of modestly dysregulated genes that led to type I interferon signaling and the associated proliferative defects of miR-155-deficient CD8 + T cells.
Interferon signaling contributes to the proliferative defect Antigen-specific CD8 + T cells downregulate expression of the type I interferon-associated transcription factor STAT1 as a means of overcoming type I interferon-induced inhibition during infection with lymphocytic choriomeningitis virus 23 . As microarray analysis suggested that type I interferon signaling and STAT pathways may be augmented in miR-155-deficient CD8 + T cells, we assessed the A r t i c l e s STAT1 signaling pathway. In vitro-activated miR-155-deficient CD8 + T cells had higher total STAT1 expression (Fig. 7a,b) . We also found higher total STAT1 expression in adoptively transferred miR-155-deficient OT-I cells than in their OT-I counterparts in vivo at day 10 after infection of the recipient mice with influenza virus WSN-OVA (Fig. 7c) . In vitro-activated miR-155-deficient CD8 + T cells had more phosphorylation of STAT1 at Tyr701 after IFN-β treatment than did their wild-type counterparts (Fig. 7d) . Activated miR-155-deficient OT-I CD8 + T cells had low constitutive enhanced phosphorylation of STAT1 at Tyr701 relative to that of their OT-I counterparts, even in the absence of IFN-β stimulation (Fig. 7d) . As miR-155-deficient CD8 + T cell did not produce IFN-α/β (as assayed by RT-PCR; data not shown), this constitutive STAT1 activation seemed to be independent of engagement of the IFN-αβ receptor.
As defects in signaling via the transcription factor STAT5 have been linked to the phenotype of miR-155-deficient regulatory T cells 18 and type I interferons can inhibit STAT5 signaling in T lymphocytes 35 , we also assessed STAT5 signaling in miR-155-deficient CD8 + T cells. We found that miR-155-deficient CD8 + T cells activated for 48 h had less IL-2-induced phosphorylation of STAT5 than did their wild-type counterparts (Fig. 7e) . Because miR-155-deficient CD8 + T cells had lower expression of the α-chain of the receptor for IL-2 (IL-2Rα) at that 48-hour time point, we also treated these cells with IL-15. As the expression of CD122 (IL-2Rβ) and CD132 (common γ-chain) was not affected in miR-155-deficient CD8 + T cells (data not shown), IL-15-induced phosphorylation of STAT5 would not be confounded by lower receptor expression. IL-15-induced phosphorylation of STAT5 was lower in miR-155-deficient CD8 + T cells than in their wild-type counterparts, although this difference was smaller than that noted with IL-2 (Fig. 7e) . Together these results suggested that aberrant type I interferon signaling, more activation of the STAT1 pathway and impaired common γ-chain signaling may have contributed to the defects of miR-155-deficient CD8 + T cells.
To (Fig. 7f,g ). Retroviral transduction with DN-STAT1 or DN-IRF7 did not affect OT-I cells. Although DN-STAT1 and DN-IRF7 did not fully restore the response of miR-155-deficient OT-I cells, which indicated that other signaling pathways may have contributed to the phenotype observed, these data demonstrated that the interferon signaling pathway contributed to the defect of miR-155-deficient CD8 + T cells.
DISCUSSION
Here we have demonstrated an essential role for miR-155 in generating optimal primary CD8 + T cell responses and establishing memory against viral and bacterial infections. Notably, absence of miR-155 resulted in an intrinsic defect of CD8 + T cells that affected their proliferation. Overexpression of miR-155 enhanced in vivo primary CD8 + T cell responses. Our studies have identified an important role for miR-155 in CD8 + T cell immunity.
Published studies have reported sustained upregulation of miR-155 in human T cells activated in vitro 36 . In agreement with that, we detected a large and sustained increase in miR-155 expression after in vitro activation of primary mouse CD8 + T cells. Inflammatory cytokines and type I interferon did not induce miR-155 expression in resting CD8 + T cells and resulted in only modestly more miR-155 in activated cells. Our studies suggest that stimulation via the TCR or CD28 may be the main inducer of miR-155 in CD8 + T cells. Furthermore, we found more miR-155 in vivo in effector CD8 + T cells and, to a lesser extent, in effector memory CD8 + T cells. In contrast, miR-155 expression in central memory CD8 + T cells did not differ from that in naive cells. As miR-155 overexpression enhanced the population expansion of CD8 + T cells, upregulation of miR-155 in primary CD8 + T cells may promote the rapid population expansion of effector CD8 + T cells. Thus, the amount of miR-155 expression may regulate CD8 + T cell responsiveness at different stages of differentiation. 
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A r t i c l e s Deficiency in miR-155 in vivo resulted in a significantly smaller memory CD8 + T cell pool after infection. Populations of both shortlived effector cells and memory precursor effector cells were smaller during the primary response in miR-155 deficiency. Therefore, miR-155 seemed to be required for the generation of memory precursor cells during the primary response, and this resulted in a much smaller pool of memory cells later. Our studies, however, did not address the role of miR-155 during the differentiation or maintenance of memory. The expression of miR-155 in central memory CD8 + T cells was similar to that of quiescent naive cells, but effector memory cells had higher miR-155 expression. This may indicate that miR-155 has a role in established memory cells and may contribute to the functional differences between central and effector memory CD8 + T cells. Overall, our study has provided evidence of an important role for miR-155 during the generation of memory precursor CD8 + T cells, but its role in memory differentiation or maintenance remains to be established.
TCR signaling and cytokine production were not affected by miR-155 deficiency, and the global diminished abundance of miR-155-deficient CD8 + T cells in all tissues challenged the idea of a trafficking defect. CD8 + T cells deficient in miR-155 had a proliferative defect and were sensitive to type I interferon-mediated inhibition. However, miR-155 deficiency did not confer any sensitivity to apoptosis. Our findings suggest that upregulation of miR-155 during activation supports the optimal proliferation of CD8 + T cells. Other microRNAs may affect responses by perturbing migration and survival, as results obtained with Dicer-deficient CD8 + T cells suggest 9 .
An unresolved paradox for the role of type I interferon signaling in CD8 + T cell responses has been its role as a critical costimulatory signal 21, 22 and its contrasting well-known antiproliferative effect 24, 25 . Activated T cells have less induction of type I interferon-stimulated genes than do naive T cells 37 , but the mechanism behind this switch in interferon sensitivity is poorly understood. Type I interferons exert antiproliferative effects on bystander T cells 24, 25 , and virus-specific CD8 + T cells can escape this effect in part by downregulating STAT1 expression 23 . Type I interferon signaling can also inhibit signaling via IL-2 and STAT5 in T lymphocytes 35, 38 . STAT1 has an inhibitory role in T cell proliferation, as Stat1 −/− T cells proliferate faster, especially in the presence of type I interferons, as a consequence of greater STAT3 and STAT5 activation 39, 40 . Our studies suggest that miR-155 may regulate changes in responsiveness to type I interferon by affecting the STAT1 signaling pathway. Activated miR-155-deficient CD8 + T cells showed significant enrichment for the transcriptome signature associated with type I interferon signaling, had more constitutive and IFN-α/β-induced phosphorylation of STAT1, had impaired phosphorylation of STAT5 and were more susceptible to the antiproliferative effect of IFN-β. Notably, signaling via STAT1 and interferons was directly involved in the diminished population expansion of miR-155-deficient CD8 + T cells in vivo, as inhibiting these signaling pathways via DN-STAT1 and DN-IRF7 resulted in significantly enhanced miR-155-deficient CD8 + T cell responses in mice. Therefore, a hyperactive interferon signaling pathway and more activation of STAT1 in miR-155-deficient CD8 + T cells contributed to their diminished proliferation. Because miR-155-deficient CD8 + T cells made no IFN-α/β (data not shown) but had constitutive phosphorylation of STAT1 at Tyr701, it is possible that activation of the type I interferon pathway independently of cytokines and receptor interaction led to inhibition of the proliferation of miR-155-deficient CD8 + T cells. We note, however, that inhibiting interferon signaling did not fully restore the response, which indicates that additional pathways may be affected by miR-155 deficiency.
Microarray analysis of miR-155-deficient CD8 + T cells identified modest upregulation of the mRNA expression of many miR-155 targets.
Inhibiting or deleting single miR-155 target genes that had higher expression in miR-155 deficiency and encoded molecules that could participate in type I interferon signaling, such as IKKε and Bach1, did not revert the phenotype. A caveat of the inhibition of Bach1 was that the knockdown with shRNA was partial; future studies of doubly deficient mice will fully exclude the possiblity of Bach1 involvement. We interpret these results to indicate that the phenotype of miR-155-deficient CD8 + T cells was not due to the effect of a single miR-155 target with substantial upregulation but instead was due to the coordinated and modest increase in the expression of a battery of genes encoding molecules that promote activation of the type I interferon pathway and its antiproliferative effect. That is consistent with independent evidence showing that microRNAs target multiple elements of pathways that, in aggregate, affect cellular responses 27, 41, 42 . If miR-155 functions as the gatekeeper of the outcome of interferon signaling in CD8 + T cells, broad universal tempering would be better than focal and acute negative regulation. Broad tempering would adjust signaling thresholds rather than the 'off switch' effect of intensively targeting a single gene. High concentrations of interferon might still be able to overcome the effect of miR155, which would be important in some settings such as chronic infection.
Overexpression of miR-155 led to greater population expansion of primary CD8 + T cells during infection with influenza virus, which generated effector cells that made more IFN-γ and thus boosted CD8 + T cell immunity and enhanced viral clearance. The effect of miR-155 overexpression on memory, however, remains to be established. The preliminary studies noted above indicate that increasing the abundance of miR-155 in CD8 + T cells may prove useful for adoptivetherapy studies and vaccines.
Two other studies have also analyzed the effect of miR-155 deficiency on CD8 + T cell responses 19, 20 . Notably, there are some differences between some of our findings here and those reports. One study showed a modest 50% decrease in antigen-specific CD8 + T cell numbers 3 d after infection with L. monocytogenes 20 . In our study we observed no alteration in cell numbers early after adoptive transfer in two models tested (day 3 for L. monocytogenes and day 4 for influenza virus). Reasons for this discrepancy could include the use of different genetically modified L. monocytogenes that may vary in attenuation or cytokine induction, differences in the T cells with transgenic TCR expression used and the transfer of fewer T cells with transgenic TCR expression in our study. That report concluded that proliferation is not affected at day 3 of the response 20 ; however, it is unclear whether survival, altered distribution or differences in recruitment in initial activation (a concern with large numbers of T cells with transgenic TCR expression) account for the lower numbers. We observed no effect of miR-155 deficiency on CD8 + T cell numbers at early time points. This was not unexpected, as miR-155 has low expression in naive cells and is upregulated after activation. This would suggest that several days might be required for the effect of miR-155 deficiency to be observed, depending on the decay of its targets. Our gene arrays and mechanistic studies suggested that inflammatory cytokine signaling may have been affected in miR-155-deficient CD8 + T cells. That would alter the ability of these cells to sustain proliferative responses, which may be dependent on the integration of TCR and inflammatory signals.
The other study noted above concluded that miR-155-deficient CD8 + T cells 'preferentially' differentiate into central memory T cells that are able to mount secondary responses 19 . We observed no 'preferential' differentiation into central memory cells with miR-155 deficiency. The previous report, however, found very few central memory cells in the wild-type control mice 19 , which is not npg typical of a cleared infection 43 , and the study is complicated by the use of the MHV-68 infection model in which latent infection persists 44 , as well as the use of mixed-bone marrow chimeras in which the presence of other miR-155-deficient populations, such as macrophages, B cells and natural killer cells, may also affect pathogen clearance and the inflammatory response 19 . In our study we used a nonpersisting viral infection and adoptive transfer into wild-type hosts to link the effect of deficiency exclusively to the CD8 + T cells. Although we found that miR-155 deficiency resulted in fewer memory CD8 + T cells, this affected both effector memory cells and central memory cells.
Our study has shown that miR-155 deficiency profoundly impaired in vivo CD8 + T cell responses to viral and bacterial infections. Deficiency in miR-155 resulted in enhanced type I interferon signaling and diminished CD8 + T cell proliferation. The amount of miR-155 may also function as a key modulator of CD8 + T cell responses in the presence of type I interferons, determining whether type I interferons act as costimulatory signals or as inhibitors. Overexpression of miR-155 augmented CD8 + T cell responses, an effect potentially important for enhancing CD8 + T cell immunity to pathogens and tumors. Our findings have identified a previously unknown critical role for miR-155 in the regulation of CD8 + T cell responses.
METhODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: microarray data, GSE44649. 
ONLINE METhODS
Animals and infections. C57Bl/6J mice, B6.PL-Thy1a/CyJ (Thy-1.1 + ) mice, C57BL/6 Tg(TcraTcrb)1100Mjb/J (OT-I) mice, B6.SJL-Ptprca Pepcb/BoyJ (CD45.1 + ) mice and Ikbke −/− mice (all from The Jackson Laboratory), and Ikbke −/− OT-I mice, miR-155-deficient mice (on the C57Bl/6 background) and miR-155-deficient OT-I mice were kept in an barrier facility (certified by the Association for the Assessment and Accreditation of Laboratory Animal Care) at Drexel University College of Medicine. All animal work was approved by the Institutional Animal Care and Use Committee. Mice 8-10 weeks old were anesthetized with 2-2-2-tribromoethanol (250 mg per kg body weight, injected intraperitoneally; Acros) and were infected intranasally with influenza virus strain A/Puerto Rico/8/34 (PR8; a gift from W. Gerhard) or influenza virus strain A/WSN/33 expressing OVA(257-264) (WSN-OVA; a gift from D. Topham). Viral loads were measured as described 45 . Some mice were infected intravenously with 1 × 10 4 colony-forming units of OVA-expressing L. monocytogenes (a gift from H. Shen, University of Pennsylvania).
Flow cytometry. Cells were stained as described 46 with the following monoclonal antibodies: anti-CD69 (H1.2F3), anti-Thy-1.1 (HIS51), anti-Thy-1.2 (53-2.1), anti-CD4 (L3T4), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD62L (MEL-14), anti-CD44 (1M7), anti-IFN-γ (XMG1.2) and anti-TNF (MP6-XT22; all from eBioscience); anti-CD8α (53−6.7) and anti-CD25 (PC61; both from BD Biosciences). Cells were also stained with annexin V (BD Biosciences) and tetramers of H-2 b major histocompatibility complex class I loaded with NP(366-374) or OVA(257-264). Anti-CD16/32 (Fc Block; 2.4G2;BD Biosciences) was used in all staining. For annexin V staining, all buffers contained 2.5 mM CaCl 2 . For staining of intracellular cytokines, GolgiPlug (BD Biosciences), Cytofix/ Cytoperm buffer (eBioscience) and Perm/Wash buffer (eBioscience) were used according to the manufacturers' instructions. The following antibodies were used for intracellular flow cytometry: antibody to total STAT1 (1/STAT1), antibody to STAT1 phosphorylated at Tyr701 (4a) and antibody to STAT5 phosphorylated at Tyr694 (47/STAT5; all directly conjugated and from BD Biosciences); anti-IKKε (72B587; Imgenex); and phycoerythrin-conjugated donkey antibody to mouse IgG (secondary antibody; 12-4012; eBioscience). Samples were analyzed with a FACSAria (BD Biosciences). For calcium flux, the Fluo-4 NW Calcium Assay Kit (Invitrogen) was used. Purified CD8 + T cells were incubated with biotinylated anti-CD3 (145-2C11 ; eBiosciences) and then loaded for 30 min with the Fluo-4 NW dye mix, then streptavidin was added and cells were analyzed immediately with a FACSCalibur (BD Biosciences). All data were analyzed with FlowJo software (Treestar).
CD8 + T cell isolation.
For all in vitro assays, splenic naive CD8 + T cells were isolated by negative selection with magnetic beads (EasySep; Stemcell Technologies). The purity of CD8 + T cells was >92%, as determined by flow cytometry. For measurement of in vitro miR-155, highly purified (>97%) naive CD44-CD62L + and activated CD8 + T cells were obtained by sorting with a FACSAria. For analysis of the expression of miR-155 in vivo, donor CD8 + T cell populations were isolated by staining for CD44, CD62L, CD8, Thy-1.1 and Thy-1.2 (antibodies identified above) and sorting on a FACSAria. 
Culture of bone marrow-derived dendritic cells and cytokine detection.
Bone marrow-derived dendritic cells were generated from bone marrow after depletion of lymphocytes with magnetic beads (Dynabeads) and culture for 6 d with 10 ng/ml IL-4 (Peprotech) and 10 ng/ml GM-CSF (granulocytemacrophage colony-stimulating factor; Peprotech). Peptide-loaded bone marrow-derived dendritic cells were cultured with purified CD8 + T cells, and cytokines in supernatants were quantified by Mouse T H 1/T H 2 Cytometric Bead Array (BD Biosciences).
In vitro OT-I CD8 + T cell cultures, STAT signaling and proliferation assays. For analysis of proliferation in response to CFSE (carboxy fluorescein diacetate, succinimidyl ester), C57BL/6 splenocytes at a density of 1 × 10 7 cells/ml were loaded for 2 h at 37 °C with 10 µM OVA(257-264) and irradiated with 1,500 rads and then were washed twice. Purified CD8 + T cells were labeled with 5 mM CFSE (Invitrogen) and cultured for 4 d with OVA (257-264)-pulsed splenocytes and 10 U/ml of IL-2 (Roche). The decrease in the abundance of miR-155-deficient cells in a specific division ('X') was calculated as follows: [(wild-type cells in division X) -(miR-155-deficient cells in division X) / wild-type cells in division X)] × 100. For assay of the incorporation of [ 3 H]thymidine, purified CD8 + T cells were stimulated for 5 d with solid-phase anti-CD3 (0.2 µg/ml; 17A2; eBioscience) and IL-2, then were pulsed for 8 h with 1 µCi [ 3 H]thymidine, and thymidine incorporation was measured with a TopCount counter (Packard). For measurement of STAT1 and IKKε and signaling studies, CD8 + T cells were cultured for 4 d with OVA(257-264)-pulsed irradiated splenocytes, and IL-2 and STAT1 and IKKε were measured by intracellular flow cytometry. For analysis of STAT1 signaling, after 4 d of culture, cells were stimulated for 40 min with 5,000 U/ml IFNβ and then were immediately stained for phosphorylation of STAT1 at Tyr701 (antibody identified above). For STAT5 studies, purified CD8 + T cells were stimulated for 48 h with anti-CD3 (17A2; eBioscience), then were exposed for 15 min to IL-2 or IL-15, and STAT5 phosphorylation was measured by flow cytometry.
In vitro BrdU-incorporation assays. CD8 + T cells were isolated and then cultured with OVA(257-264)-pulsed irradiated splenocytes in 24-well plates in 10% FCS RPMI medium. On day 3, recombinant IL-2 (30 U/ml) was added. Cells were treated with recombinant IFN-β1 (1-1000 U/ml; Millipore) for the duration of the culture. Cells were collected on day 3 or 5. BrdU (5-bromo-2′-deoxyuridine; 10 µM) was added during the final 8 h, cells were stained with fluorescein isothioyanate-conjugated anti-BrdU (BU20a; eBioscience) and BrdU labeling was measured by flow cytometry. In some experiments, recombinant IFN-β1 was added after day 3 of culture and cells were collected on day 6. In those cultures, 2 ng/ml of recombinant mouse IL-7 and recombinant IL-15 (Peprotech) and 5 U/ml of recombinant IL-2 were also added on day 3.
Quantitative real-time PCR. For in vitro measurement of miR-155, sorted CD8 + T cells were stimulated for 1-5 d with anti-CD3 (0.5 µg/ml; 17A2; eBioscience) and anti-CD28 (10 µg/ml; 37.51; eBioscience). For in vivo studies, sorted CD8 + T cells were used. Total RNA, including microRNA, was extracted with an miRNeasy mini kit (Qiagen), then cDNA was synthesized from 100 ng RNA with the High Capacity cDNA Reverse Transcription Assay (Applied Biosystems). The expression of miR-155 was measured by quantitative real-time PCR with the TaqMan mmu-miR-155 MicroRNA Assay (Applied Biosystems) and a 7900 HT Real-Time PCR System. The expression of 18S rRNA served as endogenous control. For measurement of Ikbke, Bach1 and Socs1, purified CD8 + T cells were cultured for 4 d with OVA(257-264)-pulsed irradiated splenocytes plus IL-2, and then CD8 + T cells were sorted by flow cytometry and RNA was isolated. Primers for Ikbke (SABiosciences), Bach1 (SABiosciences) and Socs1 (Applied Biosystems) were used to detect expression of these genes by RT-PCR. Expression of Ikbke and Bach1 was normalized to GAPDH expression, and Socs1 expression was normalized to that of 18S rRNA. Expression was evaluated by the comparative cycling threshold (∆∆C T ) method.
Experiments with siRNA and retroviral transduction. For knockdown of SOCS1 via siRNA, purified CD8 + T cells were cultured for 3 d in delivery medium (Accell SMARTpool; Dharmacon) supplemented with 3% FBS, 5 ng/ml of recombinant IL-7 and recombinant IL-15 and 1 µM control nontargeting siRNA or SOCS1-targeting siRNA (Accell SMARTpool; Dharmacon). Cells were then washed, and 3 × 10 4 cells were adoptively transferred into congeneic recipient mice. The inhibition of SOCS1 expression was confirmed by RT-PCR.
For retroviral transduction, oligonucleotide sequences encoding SOCS1-specific shRNA 47 and Bach1-specific shRNA 48 were synthesized and inserted into the RNAi-Ready pSiren RetroQ-ZsGreen Vector according to the manufacturer's instructions (Clontech). Negative control shRNA vector was provided by the manufacturer (Clontech). Retroviruses were produced in the npg
